Targeting tumor-associated CCR2 + macrophages to inhibit pancreatic cancer recurrence following irreversible electroporation
Science Advances · 2025
DOI: 10.1126/sciadv.adw2937 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2025. Verfasst von Weichen Xu und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Ultrasound, Center of Minimally Invasive Treatment for Tumor, Shanghai Tenth People's Hospital, School of Medicine, Tongji Univ…. Hauptthemen laut MEDLINE: Receptors, CCR2, Pancreatic Neoplasms, Electroporation, Tumor-Associated Macrophages. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with pronounced resistance to conventional therapies. Irreversible electroporation (IRE) is a promising therapy for PDAC; however, its clinical efficacy is limited by a high recurrence rate. Here, using a preclinical PDAC model, we characterized the tumor immune microenvironment following insufficient IRE (iIRE) through single-cell RNA sequencing. We found that iIRE induces a CCR2 + tumor-associated macrophage (CCR2 + TAM)–mediated immunosuppressive microenvironment in residual tumors. Consequently, we developed a macrophage-based proteolipid vesicle (mPLV) coencapsulating the CCR2 antagonist PF-4136309 (PF) and gemcitabine (GEM), named PF/GEM@mPLV. Our findings suggest that PF/GEM@mPLV achieves high drug accumulation within tumors through iIRE-induced inflammation. Reduction of CCR2 + TAMs enhances antitumor immunity and improves chemotherapeutic response. PF/GEM@mPLV markedly inhibits tumor recurrence following iIRE, diminishes hepatic metastases, and prolongs survival in preclinical PDAC models. These findings uncover the role of CCR2 + TAMs in iIRE-induced immunosuppression, offering a promising strategy to enhance the clinical potential of IRE in PDAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Ultrasound, Center of Minimally Invasive Treatment for Tumor, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200072, P. R. China.
- Key Laboratory of Pulsed Power Translational Medicine of Zhejiang Province, Hangzhou 311100, P. R. China.
- Department of Ultrasound, Zhejiang Hospital, Hangzhou, Zhejiang Province 310013, P. R. China.
- Department of Medical Ultrasound, Shanghai Hospital of Traditional Chinese Medicine, Shanghai 201899, P. R. China.
- Department of Ultrasound, Institute of Ultrasound in Medicine and Engineering, Zhongshan Hospital, Fudan University, Shanghai 200032, P. R. China.
- Department of Medical Ultrasound, Henan Provincial People's Hospital, School of Medicine, Henan University, Zhengzhou, Henan 450003, P. R. China.
ORCID-Profile: Weichen Xu, Shaoyue Li, Xuexia Shan, Xinhua Chen, Yincheng Gao, Dandan Shan, Huixiong Xu, Liping Sun, Wenwen Yue
Zitieren
APA
Xu, W., Li, S., Shan, X., Wang, Q., Chen, X., Wu, S., Gao, Y., Shan, D., Ding, S., Ren, W., Hou, X., Liu, S., Wang, T., Shen, Y., Niu, Z., Xu, H., Sun, L., & Yue, W. (2025). Targeting tumor-associated CCR2 + macrophages to inhibit pancreatic cancer recurrence following irreversible electroporation. Science Advances. https://doi.org/10.1126/sciadv.adw2937
Vancouver
Xu W, Li S, Shan X, Wang Q, Chen X, Wu S, et al. Targeting tumor-associated CCR2 + macrophages to inhibit pancreatic cancer recurrence following irreversible electroporation. Science Advances. 2025. doi:10.1126/sciadv.adw2937
BibTeX
@article{Xu2025,
author = {Xu, Weichen and Li, Shaoyue and Shan, Xuexia and Wang, Qiao and Chen, Xinhua and Wu, Shengbo and Gao, Yincheng and Shan, Dandan and Ding, Shisi and Ren, Weiwei and Hou, Xiaodong and Liu, Shuo and Wang, Taixia and Shen, Yuting and Niu, Zhiyuan and Xu, Huixiong and Sun, Liping and Yue, Wenwen},
title = {Targeting tumor-associated CCR2 + macrophages to inhibit pancreatic cancer recurrence following irreversible electroporation},
journal = {Science Advances},
year = {2025},
doi = {10.1126/sciadv.adw2937}
}
EUVIMED